Basilea Boosts 2026 Guidance on Strong Half-Year Results, Fosmanogepix Progress
Event summary
- Basilea reported a 14% year-on-year revenue increase to CHF 119 million in H1 2026.
- Operating profit surged 32% to CHF 32 million, with net profit up 77% to CHF 28 million.
- Fosmanogepix phase 3 program remains on track for 2028 regulatory submission.
- Full-year 2026 guidance raised: operating profit now expected to grow 40%, up from prior 20% target.
- Cash position strengthened to CHF 176 million, with debt reduced by CHF 150 million since 2022.
The big picture
Basilea's strong H1 2026 results reflect successful execution of its dual commercial/R&D strategy in the anti-infectives space. The company's ability to balance aggressive pipeline investment with profitability improvements positions it favorably against peers facing similar funding challenges. The raised guidance suggests confidence in sustaining this momentum through 2026, though execution risks remain in both clinical development and commercial expansion.
What we're watching
- Pipeline Execution
- Whether Basilea can maintain its aggressive R&D investment pace while sustaining profitability growth.
- Commercial Momentum
- The pace at which Zevtera gains US market traction following expanded hospital coverage.
- Regulatory Timing
- How potential 2028 fosmanogepix approval aligns with competitive landscape developments.